Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
Semaglutide is popularly available as Ozempic for diabetes and Wegovy for weight loss. Semaglutide also led to a 41% lower risk of worsening heart failure (2.8% versus 4.7% with placebo).Friday, The Lancet published a new pooled, participant-level analysis of patients with heart failure with mildly reduced ejection fraction or heart failure with preserved ejection fraction (HFpEF) from Novo Nordisk A/S' (NYSE:NVO) SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials.
周五，《柳叶刀》发布了来自诺和诺德A/S（纽约证券交易所代码：NVO）Select、FLOW、step-HFPEF和stepHFPEF Dm试验中射血分数略有下降的心力衰竭患者或射血分数保持不变的心力衰竭患者的全新合并分析。
According to the analysis, semaglutide led to a 31% reduced risk of combined cardiovascular (CV) death or worsening heart failure (HF) events, based on an incidence of 5.4% in patients assigned to semaglutide versus 7.5% in those assigned to placebo.
根据分析，索玛鲁肽使合并心血管（CV）死亡或心力衰竭（HF）事件恶化的风险降低了31％，而分配给索马鲁肽的患者的发病率为5.4％，而安慰剂患者的发病率为7.5％。
Also Read: Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices.
另请阅读：诺和诺德不以毒品卡特尔的身份运作，首席执行官为美国对Ozempic的定价辩护，以免受到对药品价格居高不下的批评。
Semaglutide is popularly available as Ozempic for diabetes and Wegovy for weight loss. Semaglutide also led to a 41% lower risk of worsening heart failure (2.8% versus 4.7% with placebo).
Semaglutide 通常以Ozempic的形式用于糖尿病，Wegovy的形式普遍用于减肥。索玛鲁肽还使心力衰竭恶化的风险降低了41％（2.8％，安慰剂为4.7％）。
There was no significant effect on the incidence of CV death (3.1% with semaglutide versus 3.7% with placebo).
对心血管死亡发生率没有显著影响（索玛鲁肽为 3.1%，安慰剂为 3.7%）。
Statistical analyses were not adjusted for multiplicity, and hazard ratios should not be used to infer definitive treatment effects. The study was a pooled, post hoc participant-level analysis of 3,743 patients.
统计分析未根据多重性进行调整，也不应使用危害比率来推断明确的治疗效果。该研究是对3,743名患者进行的事后参与者级别的合并分析。
Adverse events leading to treatment discontinuation occurred in 21% of patients in the semaglutide group and 13.9% in the placebo group.
导致停止治疗的不良事件发生在索玛鲁肽组的患者中有21％，在安慰剂组中发生13.9％的患者。
Gastrointestinal disorders leading to treatment discontinuation occurred in 11.1% of patients in the semaglutide group and 2.7% in the placebo group.
导致停止治疗的胃肠道疾病发生在索玛鲁肽组的患者中有11.1％，在安慰剂组中出现2.7％的患者。
Semaglutide is not approved in the US to reduce heart failure outcomes.
Semaglutide在美国未获批准用于减少心力衰竭的结果。
Research also showed that GLP-1 agonists, drugs like Ozempic, Wegovy, and Eli Lilly And Co's (NYSE:LLY) Zepbound, are investigating their potential to address a range of other conditions, including addiction, sleep apnea, and even cancer.
研究还表明，GLP-1 激动剂，即Ozempic、Wegovy和礼来公司（纽约证券交易所代码：LLY）Zepbound等药物，正在研究其治疗一系列其他疾病的潜力，包括成瘾、睡眠呼吸暂停甚至癌症。
These medications are showing early promise in preventing several common cancers linked to obesity, such as breast, colon, liver, and ovarian cancers, by acting on the brain to regulate hormones, slow digestion, and reduce hunger.
这些药物通过作用于大脑调节激素、减缓消化和减少饥饿感，在预防几种与肥胖相关的常见癌症（例如乳腺癌、结肠癌、肝癌和卵巢癌）方面显示出早期的希望。
Price Action: At last check on Friday, NVO stock was up 0.80% at $138.61.
价格走势：在周五的最后一次检查中，NVO股价上涨0.80％，至138.61美元。
- NuCana Stock Plunges On Colorectal Combo Therapy Trial Setback, Ends Mid-Stage Study After Disappointing Data.
- NuCana股票因结直肠组合疗法试验受挫而暴跌，在令人失望的数据后结束了中期研究。
Image Via Shutterstock
图片来自 Shutterstock